skip to content
Opportunities for improving the drug development process : results from a survey of industry and the FDA Preview this item
ClosePreview this item
Checking...

Opportunities for improving the drug development process : results from a survey of industry and the FDA

Author: Ernst R Berndt; Adrian H B Gottschalk; Matthew W Strobeck; National Bureau of Economic Research.
Publisher: Cambridge, Mass. : National Bureau of Economic Research, 2005.
Series: Working paper series (National Bureau of Economic Research), no. 11425.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
"In the United States, the Food and Drug Administration (FDA) agency is responsible for regulating the safety and efficacy of biopharmaceutical drug products. Furthermore, the FDA is tasked with speeding new medical innovations to market. These two missions create an inherent tension within the agency and between the agency and key stakeholders. Oftentimes, communications and interactions between regulated companies  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Ernst R Berndt; Adrian H B Gottschalk; Matthew W Strobeck; National Bureau of Economic Research.
OCLC Number: 60670862
Notes: June 2005.
Title from first page of PDF document.
Description: 1 online resource (40 pages) : illustrations.
Series Title: Working paper series (National Bureau of Economic Research), no. 11425.
Responsibility: Ernst R. Berndt, Adrian H.B. Gottschalk, Matthew W. Strobeck.

Abstract:

"In the United States, the Food and Drug Administration (FDA) agency is responsible for regulating the safety and efficacy of biopharmaceutical drug products. Furthermore, the FDA is tasked with speeding new medical innovations to market. These two missions create an inherent tension within the agency and between the agency and key stakeholders. Oftentimes, communications and interactions between regulated companies and the FDA suffer. The focus of this research is on the interactions between the FDA and the biopharmaceutical companies that perform drug R & D. To assess the current issues and state of communication and interaction between the FDA and industry, we carried out a survey of industry leadership in R & D and regulatory positions as well as senior leadership at the FDA who have responsibility for drug evaluation and oversight. Based on forty-nine industry and eight FDA interviews we conducted, we found that industry seeks additional structured and informal interactions with the FDA, especially during Phase II of development. Overall, industry placed greater value on additional communication than did the FDA. Furthermore, industry interviewees indicated that they were willing to pay PDUFA-like fees during clinical development to ensure that the FDA could hire additional, well-qualified staff to assist with protocol reviews and decision-making. Based on our survey and discussions, we uncovered several thematic opportunities to improve interactions between the FDA and industry and to reduce clinical development times: 1) develop metrics and goals at the FDA for clinical development times in exchange for PDUFA like fees; 2) establish an oversight board consisting of industry, agency officials, and premier external scientists (possibly at NIH or CDC) to evaluate and audit retrospectively completed and terminated drug projects; and 3) construct a knowledge database that can simultaneously protect proprietary data while allowing sponsor companies to understand safety issues and problems of previously developed/failed drug programs. While profound scientific and medical challenges face the FDA and industry, the first step to reducing development times and associated costs and facilitating innovation is to provide an efficient regulatory process that reduces unnecessary uncertainty and delays due to lack of communication and interaction"--National Bureau of Economic Research web site.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.

Similar Items

Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/60670862> # Opportunities for improving the drug development process : results from a survey of industry and the FDA
    a schema:MediaObject, schema:Book, schema:CreativeWork ;
   library:oclcnum "60670862" ;
   library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/31859#Place/cambridge_mass> ; # Cambridge, Mass.
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/mau> ;
   schema:about <http://id.worldcat.org/fast/1204155> ; # United States
   schema:about <http://dewey.info/class/330/> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/31859#Topic/drug_development_united_states_evaluation> ; # Drug development--United States--Evaluation
   schema:bookFormat schema:EBook ;
   schema:contributor <http://viaf.org/viaf/135446122> ; # National Bureau of Economic Research.
   schema:contributor <http://viaf.org/viaf/62658981> ; # Matthew W. Strobeck
   schema:contributor <http://viaf.org/viaf/55234516> ; # Adrian H. B. Gottschalk
   schema:creator <http://viaf.org/viaf/9909192> ; # Ernst R. Berndt
   schema:datePublished "2005" ;
   schema:description ""In the United States, the Food and Drug Administration (FDA) agency is responsible for regulating the safety and efficacy of biopharmaceutical drug products. Furthermore, the FDA is tasked with speeding new medical innovations to market. These two missions create an inherent tension within the agency and between the agency and key stakeholders. Oftentimes, communications and interactions between regulated companies and the FDA suffer. The focus of this research is on the interactions between the FDA and the biopharmaceutical companies that perform drug R & D. To assess the current issues and state of communication and interaction between the FDA and industry, we carried out a survey of industry leadership in R & D and regulatory positions as well as senior leadership at the FDA who have responsibility for drug evaluation and oversight. Based on forty-nine industry and eight FDA interviews we conducted, we found that industry seeks additional structured and informal interactions with the FDA, especially during Phase II of development. Overall, industry placed greater value on additional communication than did the FDA. Furthermore, industry interviewees indicated that they were willing to pay PDUFA-like fees during clinical development to ensure that the FDA could hire additional, well-qualified staff to assist with protocol reviews and decision-making. Based on our survey and discussions, we uncovered several thematic opportunities to improve interactions between the FDA and industry and to reduce clinical development times: 1) develop metrics and goals at the FDA for clinical development times in exchange for PDUFA like fees; 2) establish an oversight board consisting of industry, agency officials, and premier external scientists (possibly at NIH or CDC) to evaluate and audit retrospectively completed and terminated drug projects; and 3) construct a knowledge database that can simultaneously protect proprietary data while allowing sponsor companies to understand safety issues and problems of previously developed/failed drug programs. While profound scientific and medical challenges face the FDA and industry, the first step to reducing development times and associated costs and facilitating innovation is to provide an efficient regulatory process that reduces unnecessary uncertainty and delays due to lack of communication and interaction"--National Bureau of Economic Research web site."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/31859> ;
   schema:inLanguage "en" ;
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/31859#Series/nber_working_paper_series> ; # NBER working paper series ;
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/31859#Series/working_paper_series_national_bureau_of_economic_research> ; # Working paper series (National Bureau of Economic Research) ;
   schema:name "Opportunities for improving the drug development process : results from a survey of industry and the FDA"@en ;
   schema:productID "60670862" ;
   schema:publication <http://www.worldcat.org/title/-/oclc/60670862#PublicationEvent/cambridge_mass_national_bureau_of_economic_research_2005> ;
   schema:publisher <http://experiment.worldcat.org/entity/work/data/31859#Agent/national_bureau_of_economic_research> ; # National Bureau of Economic Research
   schema:url <http://ezproxy.eui.eu/login?url=http://papers.nber.org/papers/> ;
   schema:url <http://0-papers.nber.org.biblio.eui.eu/papers/> ;
   schema:url <http://papers.nber.org/papers/w11425> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/60670862> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/31859#Agent/national_bureau_of_economic_research> # National Bureau of Economic Research
    a bgn:Agent ;
   schema:name "National Bureau of Economic Research" ;
    .

<http://experiment.worldcat.org/entity/work/data/31859#Place/cambridge_mass> # Cambridge, Mass.
    a schema:Place ;
   schema:name "Cambridge, Mass." ;
    .

<http://experiment.worldcat.org/entity/work/data/31859#Series/nber_working_paper_series> # NBER working paper series ;
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/60670862> ; # Opportunities for improving the drug development process : results from a survey of industry and the FDA
   schema:name "NBER working paper series ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/31859#Series/working_paper_series_national_bureau_of_economic_research> # Working paper series (National Bureau of Economic Research) ;
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/60670862> ; # Opportunities for improving the drug development process : results from a survey of industry and the FDA
   schema:name "Working paper series (National Bureau of Economic Research) ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/31859#Topic/drug_development_united_states_evaluation> # Drug development--United States--Evaluation
    a schema:Intangible ;
   schema:hasPart <http://id.loc.gov/authorities/subjects/sh97007921> ;
   schema:name "Drug development--United States--Evaluation"@en ;
    .

<http://id.worldcat.org/fast/1204155> # United States
    a schema:Place ;
   schema:name "United States" ;
    .

<http://viaf.org/viaf/135446122> # National Bureau of Economic Research.
    a schema:Organization ;
   schema:name "National Bureau of Economic Research." ;
    .

<http://viaf.org/viaf/55234516> # Adrian H. B. Gottschalk
    a schema:Person ;
   schema:familyName "Gottschalk" ;
   schema:givenName "Adrian H. B." ;
   schema:name "Adrian H. B. Gottschalk" ;
    .

<http://viaf.org/viaf/62658981> # Matthew W. Strobeck
    a schema:Person ;
   schema:familyName "Strobeck" ;
   schema:givenName "Matthew W." ;
   schema:name "Matthew W. Strobeck" ;
    .

<http://viaf.org/viaf/9909192> # Ernst R. Berndt
    a schema:Person ;
   schema:familyName "Berndt" ;
   schema:givenName "Ernst R." ;
   schema:name "Ernst R. Berndt" ;
    .

<http://www.worldcat.org/title/-/oclc/60670862>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
   schema:about <http://www.worldcat.org/oclc/60670862> ; # Opportunities for improving the drug development process : results from a survey of industry and the FDA
   schema:dateModified "2017-12-23" ;
   void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.